FDA Advisory Committee Voted in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection TestQ3 Galleri®Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Volume Increased ~36%
SUNNYVALE, Calif., Oct. 27, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the
SUNNYVALE, Calif., Oct. 21, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the
SAN DIEGO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Picard Medical, Inc. (NYSE:PMI), Methode Electronics, Inc.
GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early DetectionGRAIL to Present Two Abstracts
SUNNYVALE, Calif., Sept. 23, 2026 /PRNewswire/ -- GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular and Clinical Genetics
SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the
MENLO PARK, Calif., Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the
MENLO PARK, Calif., Aug. 7, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the U.S. Food and Drug
Q2 Galleri® Test Volume Increased 35% to More Than 61,000 Year-Over-Year, and Galleri Revenue Grew 24% to $42.6 Million Galleri Test Volume and Revenue are up 42% and 30% Year-Over-Year, Respectively, for the First Half
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Grail To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in
SAN FRANCISCO, Aug. 4, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in GRAIL, Inc. (NASDAQ:GRAL) that a securities fraud class action lawsuit has been filed, and the firm is actively urging
SAN FRANCISCO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in GRAIL, Inc. (NASDAQ:GRAL) that a securities fraud class action lawsuit has been filed, and the firm is actively
LOS ANGELES, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GRAIL, Inc.
